A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Twice a Week in Adult Patients With Advanced Solid Malignancies Including Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 29 Sep 2009
At a glance
- Drugs AZD 4877 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 29 Sep 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
- 22 Jul 2008 The expected completion date for this trial is now 1 Nov 2009, from clinicaltrials.gov record.